Alzheimer's research is at a critical point with initial therapies emerging, but more efficient drugs are needed. Research focuses on early treatments, inflammation's role, and overcoming funding challenges. Biomarkers are vital.
Researchers identify cancer drugs (Letrozole, Irinotecan) that may reverse Alzheimer's brain changes by targeting gene expression. Combination therapy shows promise in mouse model, paving way for clinical trials.
High insulin resistance (TyG index) may flag early Alzheimer's patients at 4x greater risk of rapid cognitive decline, offering new treatment possibilities. Metabolic stress is key.
